Exploring the use of a general equilibrium method to assess the value of a malaria vaccine: an application to Ghana by Yerushalmi, Erez et al.
  
 
Exploring the use of a general equilibrium method to assess 
the value of a malaria vaccine: an application to Ghana  
Erez Yerushalmi PhD Economics*a, Priscillia Hunt PhD Economicsb, Stijn Hoorens 
MScc, Christophe Sauboin MScd, Richard Smith PhDe 
Published in: Medical Decision Making (MDM) Policy & Practice, 2019, 
https://doi.org/10.1177/2381468319894345 
 
a Birmingham City Business School, Birmingham City University, UK; Institute for 
Employment Research (IER), University of Warwick, Coventry, UK  
b RAND Corporation, Santa Monica, USA; Institute for the Study of Labor (IZA) 
c RAND Europe, Brussels, Belgium 
d Department of Health Economics, GSK, Wavre, Belgium 
e College of Medicine and Health, University of Exeter, UK 
 
*Corresponding Author: 
Erez Yerushalmi 
Birmingham City Business School, Birmingham City University, UK 
Tel: +44 (0)1213004419 
E-mail address: erez.yerushalmi@bcu.ac.uk 
 
E-mail addresses:  
Erez Yerushalmi: erez.yerushalmi@bcu.ac.uk 
Priscillia Hunt: phunt@rand.org 
Stijn Hoorens: hoorens@rand.org 
Christophe Sauboin: christophe.j.sauboin@gsk.com 
Richard Smith: rich.smith@exeter.ac.uk 
 
Financial support for this study was provided by GlaxoSmithKline Biologicals SA 
(TrackHO number: HO-13-13516). The funding agreement ensured the authors’ 
independence in designing the study, interpreting the data, writing, and publishing 
the report. The following author is employed by the sponsor: Christophe Sauboin. 
 
Journal: Medical Decision Making Policy & Practice  
Abbreviations: CGE, computable generalized equilibrium; GAVI, Global Alliance for 
Vaccines and Immunization; GDP, gross domestic product; IRS, indoor residual 
spraying; ITN, insecticide-treated net; LiST, Lives Saved tool; SMC, seasonal malaria 
  
 
chemoprevention; WHO, World Health Organization  
  
 
 
Abstract 
Background: Malaria is an important health and economic burden in sub-Saharan 
Africa. Conventional economic evaluations typically consider only direct costs to the 
healthcare system and government budgets. This paper quantifies the potential 
impact of malaria vaccination on the wider economy, using Ghana as an example. 
Methods: We used a computable general equilibrium model of the Ghanaian 
economy to estimate the macroeconomic impact of malaria vaccination in children 
under the age of five, with a vaccine efficacy of 50% against clinical malaria and 20% 
against malaria mortality. The model considered changes in demography and labor 
productivity, and projected gross domestic product (GDP) over a time frame of 30 
years. Vaccine coverage ranging from 20% to 100% was compared with a baseline 
with no vaccination. 
Results: Malaria vaccination with 100% coverage was projected to increase the 
GDP of Ghana over 30 years by US$6.93 billion (in 2015 prices) above the baseline 
without vaccination, equivalent to an increase in annual GDP growth of 0.5%. 
Projected GDP per capita would increase in the first year due to immediate 
reductions in time lost from work by adults caring for children with malaria, then 
decrease for several years as reductions in child mortality increase the number of 
dependent children, then show a sustained increase after Year 11 due to long-term 
productivity improvements in adults resulting from fewer malaria episodes in 
childhood. 
Conclusion: Investing in improving childhood health by vaccinating against malaria 
could result in substantial long-term macroeconomic benefits when these children 
enter the workforce as adults. These macroeconomic benefits are not captured by 
conventional economic evaluations and constitute an important potential benefit of 
vaccination. 
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Introduction  
Malaria remains an important public health burden in sub-Saharan Africa, with an 
estimated 407,000 malaria deaths in 2016.1 The clinical symptoms of malaria range 
from non-specific mild febrile illness to life-threatening disease with coma, respiratory 
distress, severe anemia or shock.2 In addition to established preventive malaria 
interventions, such as insecticide-treated nets (ITNs), indoor residual spraying (IRS) 
and seasonal malaria chemoprevention (SMC), the RTS,S malaria vaccine candidate 
is now under evaluation after having been piloted with children (0-5 years of age) in 
moderate to high transmission settings in sub-Saharan Africa as recommended by 
the World Health Organization (WHO).22 Decisions on country-level vaccine 
introduction will need to take into account the potential public health impact of 
vaccination, together with an evaluation of its potential budgetary and economic 
impact.  
Commonly used forms of economic evaluation such as cost-effectiveness analysis,3 4 
5 budget impact analysis 6 7 8 and budget optimization analysis 9 are typically limited 
to considering direct costs to the healthcare system and governmental budgets.10 
Analyses of this type for the RTS,S vaccine are presented elsewhere [[Citation to 
the CE-BI paper to be added here when available]] [[Citation to BOM paper to 
be added here when available]]. However, many of the costs of disease are borne 
at household level. For example, households may have to pay for treatment and 
transport to a clinic, and may lose income if a parent has to take time away from work 
to care for a child with malaria. A study in Ghana, Kenya and Tanzania published in 
2013 estimated that 55–70% of the costs of an episode of malaria were borne by 
households.11 It is possible to include some of these household costs, such as lost 
income and out-of-pocket expenditure on treatment and transport, in economic 
evaluations that take a societal perspective. However, even this does not capture the 
effect of changes in household behavior on the wider economy. 
Malaria indirectly effects economic growth because households contribute to the 
economy by providing labor to firms, by producing goods and services, and by 
consuming goods and services. When a parent has to take time away from work to 
care for a child with malaria, not only does the affected household lose income, the 
employer also loses the value of the lost work time. Furthermore, the household will 
have less to spend on consumption, thereby reducing the income of individuals and 
  
 
firms from which the household would otherwise have bought goods or services. 
Other examples of indirect effects are reduced investment in education per child, 
reduced educational attainment resulting from missed schooldays due to illness, 
lower skills due to impaired cognitive development, lower household savings, and 
reductions in tourism and foreign direct investment.12 Cross-country regression 
analysis using data from 1965–1990 estimated that countries with intensive malaria 
had an economic growth that was 1.3% lower per person per year than countries 
without malaria, after taking into account factors such as initial income level, overall 
health and tropical location.13  
Conventional economic evaluations (such as partial equilibrium models) do not 
account for indirect effects of the disease on the wider economy, and therefore 
provide only a partial view of the economic benefit of interventions to reduce 
disease.10 14 15 16 17 Computable generalized equilibrium (CGE) models offer a 
promising approach to exploring these wider economic effects.18 CGE models 
consider different, but interrelated, elements of the economy including households, 
government, production sectors (such as manufacturing, agriculture, and transport), 
capital, labor and foreign trade. The economic relationships between them is 
calibrated using a social accounting matrix for national income and input–output data 
by sector.19 Contrary to other methods, general equilibrium can account for wider 
changes that result from behavior adjustments (e.g. consumption and production) of 
all key economic agents. For this reason, this approach is highly suitable to estimate 
the impact of a positive productivity shock after reducing a widespread disease. 
CGE models have been applied to simulate the economic impact of antimicrobial 
resistance 20 and pandemic influenza.19 21 22 In our paper, we explore the broader 
economic impact of malaria vaccination on the Ghanaian economy (An early draft of 
this paper was catalogued by an ISPOR conference).23 The impact of malaria 
vaccination was measured by considering the economic impacts of changes in: (1) 
malaria-related child mortality, (2) short-term productivity due to caregiving for a child 
with malaria (which alters the contribution of a malaria-affected household to the 
economy and the resources available for household consumption). Finally, (3) long-
term labor productivity resulting from impaired cognitive development and missed 
schooling due to malaria in childhood. 
 
  
 
Methods 
Model structure 
We developed a computable general equilibrium (CGE) model that includes the 
effects of malaria on demography and labor productivity. The core CGE model 
considers a range of economic agents in Ghana, including the government, 
households, firms and the rest of the world. The economic behavior and interactions 
of each agent were modelled using standard preference functional forms, based on 
established microeconomic theory and computational methods. The model was 
numerically simulated using the computer program GAMS and its MPSGE solver. 24 
25 GAMS is one of the most commonly used software environment for applied CGE 
modelling. (See www.gams.com for further information.) 
The economy was assumed a small open economy. Firms select the combination of 
labor, goods and service inputs required to produce their output of goods and/or 
services and maximize their profits. Households maximize their utility by offering their 
labor to firms, consuming goods and services and saving from their income. The 
model finds the equilibrium at which prices of all goods and services are such that 
the quantity supplied equals the quantity demanded across all sectors. (We provide 
the full model description in the online supplementary appendix of this paper, 
including the GAMS/MPSGE code.) 
The model’s equations are calibrated to the 2007 social accounting matrix (SAM) of 
Ghana in Breisinger et al.26 27 This is a table expressed in terms of incomes and 
expenditures (i.e., a double entry accounting method) which is now a standard 
approach to calibrate functional form to real-life data.28 The SAM is subsequently 
updated to 2015 US$ by chaining the consumer price index and exchange rate. 
The SAM provides measures for three labor skill-types (self-employed, skilled and 
unskilled), capital, and land, and 90 types of household characterized by 
administrative district, rural or urban location, and income level. We link the 
administrative districts to five ecological zones with differences in malaria incidence 
(further details provided shortly). Furthermore, we assume that the government 
provided a fixed level of goods and services to the population based on tax revenues. 
The model projects 30 years forwards, a period selected because it is long enough to 
capture effects on the adult labor force of improved health in childhood. 
  
 
Demographic model 
Population demographics over the model time horizon were modelled using the 
existing DemProj demographic model from the Spectrum Policy Modeling System of 
the Health Policy Project, which projects population size and composition based on 
fertility, mortality and migration.29 The model was adapted to account for malaria-
specific mortality and regional variations in Ghana. It was assumed that any changes 
in demographic parameters such as migration and fertility rates were not affected by 
any interventions to prevent malaria. 
Impact of malaria 
The effect of malaria was taken into account in the model in three ways. First, the 
demographic model included the specific effect of malaria on child mortality, 
estimated by combining projected clinical malaria episodes with a case-fatality rate. 
Second, for each episode of malaria occurring in a child under the age of five, the 
model estimated the immediate productivity loss resulting from adult caregivers 
losing time from work. Third, for children exposed to several episodes of malaria 
during childhood, the model considered long-term reductions in their productivity as 
adults resulting from missed schooling, greater susceptibility to other health problems 
and cognitive impairment. Children were assumed to enter the labor force at the age 
of 15 years. 
Note that episodes of malaria occurring in adults cause productivity losses due to 
absence from work or loss in productivity while at work. However, since we assume 
that the vaccine is provided only to children, its effect cancels out between scenarios. 
Malaria episodes were based on regional malaria epidemiology corresponding to five 
ecological zones with differences in malaria incidence. These are presented in Figure 
1.  The occurrence of malaria episodes ranged from 0 to a maximum of 9, and was 
modelled using a Poisson distribution, with a distribution mean equal to the mean 
baseline number of clinical malaria episodes in each zone (Table 1).  
Episodes of malaria occurring in children resulted in productivity losses when an 
adult had to take time away from work to care for the sick child (Table 1). 
Furthermore, individuals experiencing multiple episodes of malaria as children were 
assumed to experience long-term productivity losses throughout their working lives 
as adults due to lower skills or compromised health. In people with two episodes of 
childhood malaria, this was modelled as a 10% reduction in productivity, and in those 
  
 
with three or more episodes as a 25% reduction in productivity, based on published 
literature (Table 1). 
 
Figure 1: Mapping administrative districts onto malaria ecological zones 
 
Note: the figure shows the link between administrative regions and malaria ecological zones. 
 
 
 
 
 
 
  
  
 
Table 1. Key input data used in the model  
Parameter Value Source 
Total number of working 
days per year 
235 Authors’ assumption 
Range of malaria episodes 
per person-year 
0–9 Authors’ assumption 
Event distribution Poisson Smith et al 2006 31 
Baseline mean number of 
malaria episodes per year 
Age 0–4 years, age 5–64 
years 
 
National a 1.0, 0.5 Asante et al 2011 32 
Regional b  South African Medical 
Research Council 2002 33 
 Accra 0.53, 0.27  
 Coast 0.86, 0.43   
 Forest 1.62, 0.81   
 North Savannah 1.29, 0.65  
 South Savannah 0.69, 0.35  
Adult productivity loss for child’s episode of malaria  
Days absent from work to 
provide care 
2 Aikins 1995,34 Cropper et al 
2000,35 Ettling and Shepard 
1991,36 Ettling et al 1994,37 
Guiguemdé et al 1997,38 
Leighton and Foster 1993,39 
Sauerborn et al 1995,40 
Asante et al 2005 41 
Productivity loss when 
absent 
100% Authors’ assumption 
Long-term productivity loss in adulthood resulting 
from malaria in early childhood 
 
Days at work but with 
compromised skills 
235 Authors’ assumption 
Productivity loss with ≤1 
episode of childhood malaria 
0% Authors’ assumption using 
Bleakley 2003,42 Cutler et al 
2010,43 Bleakley 2010 44 
Productivity loss with 2 
episodes of childhood 
malaria 
10% Authors’ assumption using 
Bleakley 2003,42 Cutler et al 
2010,43 Bleakley 2010 44 
Productivity loss with ≥3 
episodes of childhood 
malaria 
25% Authors’ assumption using 
Bleakley 2003,42 Cutler et al 
2010,43 Bleakley 2010 44 
a Asante et al. (2011) 32 find 1.3 primary-case-definition episodes per person-years in the first 18 months of life in 
Ghana. As this study applies episodes for 0 to 4 years of life, and children aged 18 months to 4 years of age have 
relatively fewer episodes of malaria, we assume 1.0 episode per person-year from 0-4 years. Without academic 
evidence on adult episodes of malaria across regions of Ghana, authors assume 50% fewer episodes for adults than 
children. 
b Derived from national mean episodes using Asante et al. (2011) 32 and population weighted mean regional malaria 
prevalence by age group in South African Medical Research Council 2002 33 
  
 
Impact of malaria interventions 
The projected impact of a malaria vaccination program was evaluated by running a 
baseline model simulation with no vaccination program (i.e. with existing malaria 
interventions only). This was then compared with intervention scenarios introducing a 
malaria vaccination program that would have a protective effect for children under the 
age of five, therefore assuming that five birth cohorts have been immunized. We 
assumed a range of coverage levels, starting at 20% coverage and increasing to 
100% coverage in increments of 20 percentage points. The vaccine efficacy in the 
model was assumed to be 20% against mortality and 50% efficacy against clinical 
malaria episodes. The model did not account for herd effects, or any impact on the 
effectiveness of other interventions. 
The effect of vaccination on mortality and demographics was estimated using the 
Lives Saved tool (LiST) from the Spectrum Policy Modeling System of the Health 
Policy Project.29 This tool estimates the impact of each level of vaccination coverage 
on childhood mortality rates, and the DemProj tool simultaneously uses this 
information to generate the resulting demographic population projections. The effect 
of malaria vaccination would be expected to reduce childhood mortality, thereby 
increasing the number of surviving children. Fertility rates are projected to decline in 
the demographic component of the model. We did not assume additional fertility 
reduction that would be indirectly caused by the reduction of malaria mortality in 
children with the vaccine. 
The effect of vaccination on productivity losses due to malaria episodes was 
estimated by reducing the number of baseline clinical malaria episodes by 50% 
(vaccine efficacy) in the proportion of children under the age of five covered in each 
vaccination scenario. The model assumed no changes in the number of malaria 
episodes in adults, since the modelled vaccination program targeted only children 
under the age of five. Therefore, the immediate change in labor productivity due to 
malaria episodes would reflect only the change in the amount of time lost by adult 
caregivers. 
The effect of vaccination on long-term productivity losses was modelled as a 
reduction in the proportion of children experiencing two or more malaria episodes, 
resulting in a lower proportion of young adults entering the workforce with impaired 
skills due to childhood malaria. 
  
 
It was assumed that the malaria vaccine costs would be funded by international 
programs such as the Global Alliance for Vaccines and Immunization (GAVI), which 
would be consistent with the malaria vaccine pilot implementation.30 
The primary model output was gross domestic product (GDP) per capita over time for 
the different vaccine coverage levels modelled, expressed in 2015 US dollar (US$). 
The model can also calculate household revenues across different socio-economic 
groups and for urban versus rural households. 
Sensitivity analysis 
In addition to the range of vaccination coverages, the impact of additional input 
parameters has been tested in a univariate sensitivity analysis. Productivity loss 
parameters and vaccine efficacy have been varied to assess the resulting variation of 
outcomes. The two most influential parameters are varied simultaneously in a 
bivariate analysis to assess larger variations.   
Results 
Table 2 shows the projected impact of increasing levels of malaria vaccine coverage 
on cumulative Ghanaian GDP over 30 years, relative to the baseline of no 
vaccination. 
At 100% malaria vaccine coverage in children under the age of five, the projected 
economic benefit over 30 years in Ghana would amount to an additional US$6.93 
billion (in 2015 prices) more than the baseline with no vaccine program. Annual mean 
GDP would increase by US$46.0 million at 20% vaccine coverage, rising to 
US$230.8 million at 100% coverage, equivalent to an increase in annual GDP growth 
of 0.1% and 0.5%, respectively. Mean annual GDP per capita (i.e. allowing for 
increases in population size resulting from reduced malaria childhood mortality) 
would grow by 0.05% at 20% vaccine coverage and by 0.25% at 100% vaccine 
coverage. This economic gain would occur despite the fact that the vaccinated 
children are not economically active. 
Figure 2 shows the projected evolution in GDP per capita over time. In the first year 
after beginning the vaccination program, projected GDP per capita would rise 
immediately compared with the baseline. This reflects the reduction in malaria 
episodes in children, which allows adults to spend more days at work instead of 
caring for sick children and thus produces an immediate increase in labor 
  
 
productivity. 
Figure 2. Projected mean annual percentage change in GDP per capita in 
Ghana over 30 years with increasing levels of malaria vaccination coverage, 
relative to baseline with no vaccination 
 
Over the subsequent years, up to Year 11, projected GDP per capita falls, as more 
children survive but they are not yet old enough to enter the labor force; so the 
dependency ratio increases. At Year 11, the first cohort of vaccinated children (those 
vaccinated at the age of four (i.e. just under the age of five) in the first year of the 
vaccination program) move into the labor force. These vaccinated children would 
have experienced fewer malaria episodes in childhood, and consequently have 
improved labor productivity resulting from fewer missed schooldays and less malaria-
related cognitive impairment. The projected GDP per capita thus begins to increase 
after Year 11, and progressively increases over the remaining timeframe of the 
model. The improved GDP per capita in this later phase of the model, after the 
children who benefited from vaccination enter the workforce, outweighs the 
temporary decrease in GDP per capita in the earlier phase when these children were 
  
 
still dependent. Therefore, the cumulative effect over the 30-year time horizon would 
be a net gain in GDP per capita (Table 2). The overall effect of malaria vaccination of 
children under the age of five behaves as an initial investment providing long-term 
economic benefits. 
Table 2. Projected impact of increasing malaria vaccine coverage on GDP in 
Ghana over 30 years, relative to baseline with no vaccination 
 Vaccine coverage in children under the age of 
five 
 20% 40% 60% 80% 100% 
Cumulative GDP (2015 US$, 
billions) 1.38  2.77  4.15  5.54  6.93  
% of total cumulative GDP 0.13% 0.26% 0.39% 0.52% 0.65% 
Annual mean GDP (2015 US$, 
millions) 46.0 92.2 138.4 184.6 230.8 
Mean annual GDP growth (%) 0.1% 0.2% 0.3% 0.4% 0.5% 
Mean annual GDP per capita growth 
(%) 0.05% 0.10% 0.15% 0.20% 0.25% 
Mean annual household disposable 
income (2015 US$, millions) 45.8 91.7 137.5 183.5 229.5 
 
We furthermore test the model by varying key parameters, for the 100% coverage 
scenario. Results are summarized in Figure 3. As expected, the model is stable 
around the mid-point estimates, and varying parameter values raise (lower) the 
vaccine’s economic benefit.  
The two parameters that have the largest impact on our results are (1) days absent 
from work to provide care for children, and (2) productivity loss with >3 episodes of 
childhood malaria (from Table 1). To provide the highest (lowest) boundary for the 
benefit of the malaria vaccine’s, we run the model with these parameters. The 
cumulative GDP for a 30-year time-horizon is between US$5.90 to 7.96 billion with 
the mid-point value US$6.93 (see results in Figure 3 and Table 2). 
Our result and the sensitivity analysis show the importance of the labor efficiency to 
the health intervention. We are more comprehensive with how malaria episodes 
affect labor efficiency by including impacts on childhood human capital development, 
  
 
children’s health on adults’ work absenteeism, and adult absenteeism due to malaria 
illnesses. Demographic projections are based on fertility, mortality, and migration; 
however, only the direct effect of malaria reduction on mortality is included in our 
model because we do not have good evidence on the fertility and migration 
responses to malaria, which could have reversed these trends. Future avenues of 
research could introduce these elements as well. 
Figure 3. Tornado diagram: change in cumulative GDP (bil. 2015 US$) with full 
coverage 
 
Discussion 
To our knowledge, this modeling study represents the first attempt to explore the 
potential macroeconomic impact of malaria vaccination in children in sub-Saharan 
Africa. Our approach uses the established economic technique of CGE modeling, 
combined with an explicit component to model the impact of malaria on the economy 
via the mechanisms of effects on childhood mortality and labor productivity.  
Taking Ghana as an example, our results indicate that a vaccination program in 
children under the age of five using a vaccine with 50% efficacy against malaria 
episodes and 20% efficacy against malaria mortality would raise projected annual 
GDP growth by 0.1% to 0.5%, depending on the level of vaccine coverage. This 
projected economic benefit is remarkable given that our model only considered the 
  
 
impact of vaccination on malaria in children. It reflects the value of investing in 
improved childhood health to obtain long-term economic benefits resulting from 
higher productivity when these healthier children enter the workforce as adults. 
Our results are likely to be conservative, because the model focuses on improved 
labor productivity resulting from improved childhood health, and does not include 
several other factors that could be affected by malaria vaccination. First, a reduction 
in childhood mortality could lead to a reduction in total fertility in the long-term 
(sometimes referred to as a ‘demographic dividend’ or ‘demographic transition’), and 
our model does not take this into account as a specific effect of malaria vaccination. 
Second, the model does not include any potential increases in trade, tourism or 
foreign investment that could result from a reduction in malaria. Third, fewer 
childhood malaria episodes would mean that households have to spend less on out-
of-pocket expenses such as treatment and transport to a clinic. They would then be 
free to divert more of their income to consumption of other goods and services, which 
would tend to increase demand in the economy and further increase GDP. This is not 
considered in the model, which will therefore tend to underestimate vaccine benefit. 
A previous study estimated the direct economic cost of malaria in children under the 
age of five in Ghana, Tanzania and Kenya using a probabilistic accounting model.11 
This study estimated a net income benefit of only US$27.8 million (in 2015 prices) 
per year for Ghana, which is much lower than our estimate of a net benefit of US$ 
229.5 million per year in household disposable income with 100% vaccine coverage. 
This difference illustrates the potential importance of CGE modelling that combines 
both direct and indirect effects, which were absent from the previous study that only 
considered direct costs. 
The results show the variation in the timing of different effects (see Figure 2). The 
vaccine intervention provides an immediate increase in GDP per capita resulting from 
fewer days lost to care for sick children, which thereafter declines in the medium-run 
as the number of dependent children in the population increases because of reduced 
childhood mortality. Finally, in the long-term, there is a sustained increase in GDP 
per capita as cohorts of vaccinated children enter the workforce with improved labor 
productivity resulting from better health in childhood. 
Only RTS,S was assessed in the current model to reduce malaria in order to capture 
its specific effect. However, several other preventive malaria interventions, mainly 
bednet distribution have been implemented in Ghana and these were assumed to be 
  
 
maintained at their current coverage for all baseline and counterfactual scenarios. 
The overall impact of intensifying preventative interventions could bring an extra 
economic growth when reducing malaria further. However if RTS,S is introduced 
when malaria has already been reduced, the potential extra gain with RTS,S will also 
be reduced. 
The model currently assumes that malaria vaccination would be costless to the 
Ghanaian economy, with the costs of the vaccine funded by programs such as GAVI. 
This is a simplified assumption, and is consistent with the funding of the pilot 
vaccination program. However, in the longer-term, Ghana may be self-financing for 
vaccines. Future research could extend the model to introduce vaccine costs and 
sources of funding, which could explore issues such as the long-term financial 
sustainability and the return on investment of potential vaccine programs. In addition, 
future research could further explore the impact of malaria vaccination on households 
at different socioeconomic levels, which could provide valuable information on the 
equity of malaria prevention programs. 
Conclusion 
We have adapted a CGE model by adding a health component to simulate the 
impact of malaria and malaria vaccination on economic growth via effects on 
demography and labor productivity. Using Ghana as an example, our results indicate 
that vaccination of children under the age of five against malaria with 100% coverage 
could increase GDP by an average of 0.5% per year over a 30-year period. Investing 
in improving childhood health by vaccinating against malaria could result in 
substantial long-term macroeconomic benefits when these children enter the 
workforce as adults. These macroeconomic benefits are not captured by 
conventional cost-effectiveness analyses, which may therefore underestimate the 
economic benefits of vaccination. 
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